Filtered By:
Source: Circulation
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 235 results found since Jan 2013.
Correction to: Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
Circulation. 2022 Nov 8;146(19):e279. doi: 10.1161/CIR.0000000000001111. Epub 2022 Nov 7.NO ABSTRACTPMID:36343108 | DOI:10.1161/CIR.0000000000001111
Source: Circulation - November 7, 2022 Category: Cardiology Source Type: research
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration
Circulation. 2022 Nov 8;146(19):1461-1474. doi: 10.1161/CIRCULATIONAHA.121.058911. Epub 2022 Nov 7.ABSTRACTThe technological evolution and widespread availability of wearables and handheld ECG devices capable of screening for atrial fibrillation (AF), and their promotion directly to consumers, has focused attention of health care professionals and patient organizations on consumer-led AF screening. In this Frontiers review, members of the AF-SCREEN International Collaboration provide a critical appraisal of this rapidly evolving field to increase awareness of the complexities and uncertainties surrounding consumer-led AF s...
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Axel Brandes Stavros Stavrakis Ben Freedman Sotiris Antoniou Giuseppe Boriani A John Camm Clara K Chow Eric Ding Johan Engdahl Michael M Gibson Gregory Golovchiner Taya Glotzer Yutao Guo Jeff S Healey Mellanie T Hills Linda Johnson Gregory Y H Lip Trudie Source Type: research
Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER
CONCLUSIONS: In DAPA-HF and DELIVER, the response to dapagliflozin was similar between men and women. Sex did not modify the treatment effect of dapagliflozin across the range of ejection fraction.PMID:36342789 | DOI:10.1161/CIRCULATIONAHA.122.062832
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Xiaowen Wang Muthiah Vaduganathan Brian L Claggett Sheila M Hegde Maria Pabon Ian J Kulac Orly Vardeny Eileen O'Meara Shelley Zieroth Tzvetana Katova Martina M McGrath Anne-Catherine Pouleur Pardeep S Jhund Akshay S Desai Silvio E Inzucchi Mikhail N Kosib Source Type: research
Correction to: Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
Circulation. 2022 Nov 8;146(19):e279. doi: 10.1161/CIR.0000000000001111. Epub 2022 Nov 7.NO ABSTRACTPMID:36343108 | DOI:10.1161/CIR.0000000000001111
Source: Circulation - November 7, 2022 Category: Cardiology Source Type: research
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration
Circulation. 2022 Nov 8;146(19):1461-1474. doi: 10.1161/CIRCULATIONAHA.121.058911. Epub 2022 Nov 7.ABSTRACTThe technological evolution and widespread availability of wearables and handheld ECG devices capable of screening for atrial fibrillation (AF), and their promotion directly to consumers, has focused attention of health care professionals and patient organizations on consumer-led AF screening. In this Frontiers review, members of the AF-SCREEN International Collaboration provide a critical appraisal of this rapidly evolving field to increase awareness of the complexities and uncertainties surrounding consumer-led AF s...
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Axel Brandes Stavros Stavrakis Ben Freedman Sotiris Antoniou Giuseppe Boriani A John Camm Clara K Chow Eric Ding Johan Engdahl Michael M Gibson Gregory Golovchiner Taya Glotzer Yutao Guo Jeff S Healey Mellanie T Hills Linda Johnson Gregory Y H Lip Trudie Source Type: research
Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER
CONCLUSIONS: In DAPA-HF and DELIVER, the response to dapagliflozin was similar between men and women. Sex did not modify the treatment effect of dapagliflozin across the range of ejection fraction.PMID:36342789 | DOI:10.1161/CIRCULATIONAHA.122.062832
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Xiaowen Wang Muthiah Vaduganathan Brian L Claggett Sheila M Hegde Maria Pabon Ian J Kulac Orly Vardeny Eileen O'Meara Shelley Zieroth Tzvetana Katova Martina M McGrath Anne-Catherine Pouleur Pardeep S Jhund Akshay S Desai Silvio E Inzucchi Mikhail N Kosib Source Type: research
A Randomized Controlled Trial Comparing Apixaban to the Vitamin K-antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 study
Conclusions: In this randomized trial comparing apixaban and VKA in patients with AF on hemodialysis with long follow-up, no differences were observed in safety or efficacy outcomes. Even on oral anticoagulation, patients with AF on hemodialysis remain at high risk of cardiovascular events. Larger randomized trials are needed to determine the optimal anticoagulation regimen for patients with AF on hemodialysis. Clinical Trial Registration: EudraCT No. 2015-005503-84, NCT02933697.PMID:36335915 | DOI:10.1161/CIRCULATIONAHA.122.062779
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Holger Reinecke Christiane Engelbertz Rupert Bauersachs G ünter Breithardt Hans-Herbert Echterhoff Joachim Ger β Karl Georg Haeusler Bernd Hewing Joachim Hoyer Sabine Juergensmeyer Thomas Klingenheben Guido Knapp Lars Christian Rump Hans Schmidt-Guertle Source Type: research
Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
CONCLUSIONS: There was inadequate power to draw any conclusion regarding rates of major or clinically relevant non-major bleeding comparing apixaban and warfarin in patients with AF and ESKD on hemodialysis. Clinically relevant bleeding events were approximately 10-fold more frequent than stroke or systemic embolism among this population on anticoagulation, highlighting the need for future randomized studies evaluating the risks versus benefits of anticoagulation among patients with AF and ESKD on hemodialysis.PMID:36335914 | DOI:10.1161/CIRCULATIONAHA.121.054990
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Sean D Pokorney Glenn M Chertow Hussein R Al-Khalidi Dianne Gallup Pat Dignaco Kurt Mussina Nisha Bansal Crystal A Gadegbeku David A Garcia Samira Garonzik Renato D Lopes Kenneth W Mahaffey Kelly Matsuda John P Middleton Jennifer A Rymer George H Sands Ra Source Type: research
Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
CONCLUSIONS: Early initiation was noninferior to delayed start of NOAC after acute ischemic stroke in patients with atrial fibrillation. Numerically lower rates of ischemic stroke and death and the absence of symptomatic intracerebral hemorrhages implied that the early start of NOAC was safe and should be considered for acute secondary stroke prevention in patients eligible for NOAC treatment.REGISTRATION: URL: http://www.CLINICALTRIALS: gov; Unique identifier: NCT02961348.PMID:36065821 | DOI:10.1161/CIRCULATIONAHA.122.060666
Source: Circulation - September 6, 2022 Category: Cardiology Authors: Jonas Oldgren Signild Åsberg Ziad Hijazi Per Wester Maria Bertilsson Bo Norrving National TIMING Collaborators Source Type: research
Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden
CONCLUSIONS: Patients with recently diagnosed atrial fibrillation and CHA2DS2-VASc score ≥4 should be considered for ERC to reduce cardiovascular outcomes, whereas those with fewer comorbidities may have less favorable outcomes with ERC.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01288352; URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2010-021258-20; URL: https://www.isrctn.com/; Unique identifier: ISRCTN04708680.PMID:35968706 | DOI:10.1161/CIRCULATIONAHA.122.060274
Source: Circulation - August 15, 2022 Category: Cardiology Authors: Andreas Rillig Katrin Borof G ünter Breithardt A John Camm Harry J G M Crijns Andreas Goette Karl-Heinz Kuck Andreas Metzner Panos Vardas Eik Vettorazzi Karl Wegscheider Antonia Zapf Paulus Kirchhof Source Type: research
Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial
CONCLUSION: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.PMID:35726631 | DOI:10.1161/CIRCULATIONAHA.122.058575
Source: Circulation - June 21, 2022 Category: Cardiology Authors: Derek S Chew Yanhong Li Patricia A Cowper Kevin J Anstrom Jonathan P Piccini Jeanne E Poole Melanie R Daniels Kristi H Monahan Linda Davidson-Ray Tristram D Bahnson Hussein R Al-Khalidi Kerry L Lee Douglas L Packer Daniel B Mark CABANA Investigators Source Type: research
